Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 235 entries
View as:

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04355494 Org: User:
Start: - End: - Due: -

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Phase: N/A Priority: Normal
NCT ID: NCT07037420 Org: User:
Start: 10/17/25 End: 11/02/27 Due: 11/02/28

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Phase: N/A Priority: Normal
NCT ID: NCT00122304 Org: User:
Start: 12/31/04 End: 11/30/06 Due: 11/30/07

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Phase: N/A Priority: Normal
NCT ID: NCT04202341 Org: User:
Start: 12/02/19 End: 12/31/29 Due: 12/31/30

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Phase: N/A Priority: Normal
NCT ID: NCT06183931 Org: User:
Start: 01/11/24 End: 10/05/27 Due: 10/05/28

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Phase: N/A Priority: Normal
NCT ID: NCT06764160 Org: User:
Start: 01/06/25 End: 01/05/26 Due: 01/05/27

Study of Multiple Doses of Danicopan in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04889690 Org: User:
Start: 05/21/16 End: 01/11/17 Due: 01/11/18

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

Phase: N/A Priority: Normal
NCT ID: NCT02345421 Org: User:
Start: 12/31/14 End: 10/31/15 Due: 10/31/16

Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging

Phase: N/A Priority: Normal
NCT ID: NCT02090179 Org: User:
Start: 12/31/13 End: 05/31/14 Due: 05/31/15

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Phase: N/A Priority: Normal
NCT ID: NCT00844545 Org: User:
Start: 05/31/09 End: 07/31/13 Due: 07/31/14

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Phase: N/A Priority: Normal
NCT ID: NCT05047523 Org: User:
Start: 09/13/21 End: 06/26/23 Due: 06/26/24

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00675844 Org: User:
Start: 05/31/08 End: 03/31/10 Due: 03/31/11

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

Phase: N/A Priority: Normal
NCT ID: NCT02293408 Org: User:
Start: 09/14/14 End: 07/11/17 Due: 07/11/18

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Phase: N/A Priority: Normal
NCT ID: NCT04320602 Org: User:
Start: 04/14/21 End: 12/20/22 Due: 12/20/23

A Study of the Effects of Food and Age on Danicopan

Phase: N/A Priority: Normal
NCT ID: NCT04551599 Org: User:
Start: 02/21/20 End: 02/03/21 Due: 02/03/22

A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously

Phase: N/A Priority: Normal
NCT ID: NCT02618512 Org: User:
Start: 10/15/15 End: 08/18/17 Due: 08/18/18

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Phase: N/A Priority: Normal
NCT ID: NCT01849562 Org: User:
Start: 04/30/13 End: 04/30/14 Due: 04/30/15

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

Phase: N/A Priority: Normal
NCT ID: NCT02324049 Org: User:
Start: 01/22/15 End: 10/16/17 Due: 10/16/18

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Phase: N/A Priority: Normal
NCT ID: NCT03406507 Org: User:
Start: 02/22/18 End: 08/25/22 Due: 08/25/23

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05396742 Org: User:
Start: 08/09/18 End: 05/21/19 Due: 05/21/20

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Phase: N/A Priority: Normal
NCT ID: NCT01892345 Org: User:
Start: 04/11/14 End: 07/17/18 Due: 07/17/19

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

Phase: N/A Priority: Normal
NCT ID: NCT05876351 Org: User:
Start: 07/14/23 End: 05/07/25 Due: 05/07/26

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Phase: N/A Priority: Normal
NCT ID: NCT05746559 Org: User:
Start: 04/06/23 End: 02/17/27 Due: 02/17/28

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Phase: N/A Priority: Normal
NCT ID: NCT05389449 Org: User:
Start: 10/28/22 End: 07/31/26 Due: 07/31/27

A Drug Interaction Study of Danicopan

Phase: N/A Priority: Normal
NCT ID: NCT04709094 Org: User:
Start: 07/28/19 End: 04/17/20 Due: 04/17/21